Table 2. T1–T2 N0 PMRT.
| Publication | No. of patients | Included population | Follow-up | PMRT | Adjuvant treatment | LRR global failure | Outcomes |
|---|---|---|---|---|---|---|---|
| 2005 Truong et al | 1505 | T1–2 N0 with TM | 7 years | No | 50.7% | 7.8% | Recursive Partitioning Analysis |
| 10 year Kaplan–Meier LRR G3 versus G1–2 → 12.1% versus 5.5% (p < 0.0001) | |||||||
| 10 year Kaplan–Meier LRR G3+LVI versus G3 without LVI → 21.2% versus 9% (p = 0.0008) |
|||||||
| 10 year Kaplan–Meier LRR for G3+T2+LVI (−) without systemic treatment versus G3+T2+LVI (−) with systemic therapy → 23.2% versus 9.2% (p < 0.001) | |||||||
| Yildrin 2007 | 502 | T1–2 N0 with TM | 77 months (6.4 years) | No | 56.2% | 2.8% | |
| MV analysis in ≤ 40 years + > 2 cm → LRR HR 5.4 (p = 0.05) | |||||||
| MV analysis in ≤ 40 years + LVI → LRR HR 9.0 (p = 0.004) | |||||||
| MV analysis in > 40 years + > 3 cm → LRR HR 8.6 (p = 0.05) | |||||||
| MV analysis in > 40 years + G3 → LRR HR 7.0 (p = 0.05) | |||||||
| MV analysis in > 40 years + LVI → LRR HR 18 (p = 0.007) | |||||||
| Estimated 10 year LRFS rates: 98% in ≤ 40 years old with 0–2 RFs (low risk) versus 44% with > 2 RF (high risk) (p < 0.0001) | |||||||
| Estimated 10 year LRFS rates: 99% in < 3 RF (low risk) in >40 years old versus 57% in patients > 3 RFs (high risk) (p < 0.0001) | |||||||
| Trovo 2012 | 159 → 54% N0 | T1–2 N0–1 with TM | 75 months (6.25 years) | PMRT in N1 | 95% | 11% | 5 year Kaplan–Meier LRR in Patients LVI (+) versus LVI (−) → 19.1% versus 3.2% (p = 0.002) |
| Kaplan–Meier LRR in Premenopausal versus postmenopausal status → 13.4% versus 4.8% (p = 0.004) | |||||||
| Kaplan–Meier LRR inER (−) versus ER (+) → 25.8% versus 4.7% (p = 0.002) | |||||||
| Kaplan–Meier LRR in G3 versus G1–2 → 16.4% versus 1.4% (p = 0.002) Kaplan–Meier LRR in patients with non or one, two, three or four LRR factors → 1.2%, 10.3%, 24.1% and 75% (p < 0.001) |
|||||||
| Rita Abi-Raad 2011 | 1136 | T1–2N0 with TM | 9 years | No | 61.6% | 5.2% | LRR MV analysis in patients with Systemic treatment → HR 0.5 (p = 0.036) |
| LRR MV analysis in patients with margins < 2 mm → HR3.3 (p = 0.001) | |||||||
| LRR MV analysis in patients with Size ≥ 2 cm → HR 2.0 (p = 0.011) | |||||||
| LRR MV analysis in patients with > 50 years old → HR 0.5 (p = 0.018) | |||||||
| LRR MV analysis in patients with ILV (+) → HR 2.7 (p = 0.002) | |||||||
| 10 year LRR Kaplan–Meier without RFs 2%; LRR with 1 RF 3.3%; LRR with 2 RF 5.8%; ≥ 3 RF, 19.7% (p < 0.0001) | |||||||
| Xing Xing Chen 2013 | 390 → 307 N0 (78.7%) | TNBC T1–2 N0–1 with TM | 60.5 months (5 years) | No | 86% | 7.9% global | RR MV analysis in patients < 50 years versus ≥ 50 years → HR 4.82 (p = 0.015) |
| LRR MV analysis in patients with N(+) 3 versus 0–2 → HR 8.76 (p = 0.03) | |||||||
| LRR MV analysis in patients with LVI (+) versus LVI (−) → HR 26.05 (p = 0.000) | |||||||
| LRR MV analysis in patients with G3 tumour versus G1–2 → HR 2.87 (p = 0.039) | |||||||
| 5 year KM LRR with 0–1 RF was 4.2%; with 2 RF 25.2%; with > 3 RF 81% (p < 0.001) | |||||||
| Ranjna Sharma 2010 | 1019 → 753 N0 | T1–2N0–1 with TM | 7.47 years | No | 76.9% | 2.3% | 10 year Kaplan–Meier LRR in N0 patients ≤ 40 years versus >40 years → 10.5% versus 1% (p < 0.0001) |
| LRR MV analisys in N0 patients ≤ 40 years → HR 2.14 (p = 0.004) | |||||||
| 10 year Kaplan–Meier LRR in T1N0 and T2N0 in ≤ 40 years old patients was 9.3% and 18.6% (p not reported) | |||||||
| Troung 2014 | 1994 pacientes | T1–2 N0 with TM | 4.3 years | No | 80.5% | LRR MV analisys Lobular histology → HR 3.48 (p = 0.003) | |
| LRR MV analisys Close or positive margins → HR 3.42 (p = 0.009) | |||||||
| LRR MV analisys Tumour size > 2 cm → HR 2.57 (p = 0.012) | |||||||
| Jessica Selz 2012 | 699 patients | T1–2 N0 with TM | 56 months (4.6 years) | – 191 PMRT with RLI – 508 without PMRT |
HT 65.5% CT 33.5% Trastuzumab 3.7% |
Freedom from LRR: 97% patients |
– LRR MV analisys in patients with with Ki67 > 20% → HR 4.18 (p < 0.0215) |
| 5 year LRRFS in PMRT versus no PMRT patients → 97.7% versus 96.8% (p = 0.663) | |||||||
| Bassam S. Abdulkarim 2011 | 768 TNBC – BCT+RT in T1–2 N0 → 233 – T1–2N0 MT with no PMRT→ 235 |
T1–2N0 with TM | 7.2 years | No | 69.9% in those with TM | LRR 10% | LRR MV analisys for MRM without RT versus BCT+RT in T1–2 N0 → HR 3.44 (p < 0.001) |
| LRR MV analisys for MRM with RT versus BCT+RT in T1–2 N0 → 0.72 (p = 0.34) | |||||||
| Joseph Hastings 2014 | 1259 patients | TNBC T1 N0 with TM | 8.5 years | No | QT 24.2% | 10 year LRR 3.2% | LRR MV analysis in patients with margins ≤ 3 mm → HR 2.97 (p = 0.02) |
| LRR MV analysis in patients in patien with G3 versus G1–2 tumours → HR 3.97 (p = 0.0002) | |||||||
| 10 year Kaplan–Meier LRR in Patients with one of these RFs versus two RFs → 2.7% versus 25% (p < 0.0001) |
G = histological grade; BCT = breast conservative treatment; NS = not significant; RLI = regional lymph node irradiation